HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. (Q41438696)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

M L Disis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M A Cheever

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

Advances in Cancer Research

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

343-371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9111870%20AND%20SRC:MED&resulttype=core&format=json

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Synthetic peptides as vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

The neu oncogene encodes an epidermal growth factor receptor-related protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Using a neural network to identify potential HLA-DR1 binding sites within proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Immunity to oncogenic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Oncogenic proteins as tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Identifying antigenic T-cell sites.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

T-cell recognition of oncogene products: a new strategy for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

The role of erbB-2 and its ligands in growth control of malignant breast epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Induction of anti-self-immunity to cure cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Clinical significance of erbB-2 (HER-2/neu) protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Development of anti-p185HER2 immunoliposomes for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Shared T cell epitopes in epithelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Proliferating dendritic cell progenitors in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Dominance and crypticity of T cell antigenic determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

neu/HER-2 cDNA vaccination and pregnancy loss

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2960103-7

7 January 2021

10.1016/S0065-230X(08)60103-7

Identifiers

DOI

0 references

1 reference